SeaStar Medical Advances AKI Trial with New Site Activations and Enrollment Milestones
• SeaStar Medical activated its 14th clinical site for the NEUTRALIZE-AKI pivotal trial, evaluating the Selective Cytopheretic Device (SCD) in adult patients with acute kidney injury (AKI).
• The NEUTRALIZE-AKI trial has enrolled 76 of the planned 200 subjects, with an interim analysis expected by mid-2025 based on the first 100 subjects.
• The annual U.S. market for SCD in adult AKI is estimated between $4.7 billion and $6.3 billion, offering a substantial return on the trial investment.
• Mayo Clinic has joined SeaStar Medical as the 15th site authorized to enroll subjects for the company’s pivotal NEUTRALIZE-AKI trial.
© Copyright 2025. All Rights Reserved by MedPath